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Abstract Recently we have shown that Mos could activate
myogenic differentiation by promoting heterodimerisation of
MyoD and E12 proteins. Here, we demonstrate that MyoD can
be efficiently phosphorylated by in vitro kinase assay with
purified Mos immunoprecipitated from transfected cells. Com-
parative two-dimensional tryptic phosphopeptide mapping com-
bined with site-directed mutagenesis revealed that Mos
phosphorylates MyoD on serine 237. Mutation of serine 237 to
a non-phosphorylable alanine (MyoD-Ala237) abolished the
positive regulation of MyoD by Mos following overexpression in
proliferating 10T1/2 cells. Taken together, our data show that
direct phosphorylation of MyoD-Ser237 by Mos plays a positive
role in increasing MyoD activity during myoblast
proliferation. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Myogenic di¡erentiation is under the control of a family of
muscle-speci¢c transcription factors (MRFs) whose MyoD is
the prototypic molecule [1]. These MRFs are basic helix^
loop^helix (bHLH) nuclear proteins [2^4] which bind to an
E-box DNA consensus sequence (CANNTG) as heterodimers
with the ubiquitous E proteins (E12 and E47) [5,6], to trans-
activate muscle genes and to e⁄ciently convert non-muscle
cells to a myogenic lineage [7,8].
Their overall activity is subject to negative and positive
regulations in response to intracellular signaling pathways
and to the expression of transcriptional accessory proteins.
An additional mechanism through which the activities of
MRFs are regulated is by di¡erential phosphorylation.
MRFs exist as phosphoproteins in vivo and their amino
acid sequence contains several potential sites of speci¢c phos-
phorylation, including consensus sites for cyclic AMP-depen-
dent protein kinase (PKA) [9], protein kinase C [10,11], cyclin-
dependent kinases [12^16] and casein kinase II (CKII) [17].
Furthermore, MRFs exhibit some speci¢c features such as
temporal expression during development, cell cycle progres-
sion, positive autoregulation loop or the targetting of di¡erent
muscular genes [18^20].
For several years we have endeavoured to characterise
mechanisms and factors that positively regulate MyoD activ-
ity. We recently reported that the proto-oncogene c-mos acti-
vated muscle di¡erentiation [21]. We further demonstrated
that the c-Mos protein interacts physically with unphosphory-
lated MyoD and that phosphorylation of the COOH domain
of recombinant MyoD by Mos promotes the formation and
DNA binding of MyoD^E12 heterodimers [22^23].
In this report we show by tryptic phosphopeptide mapping
and mutational analysis that Mos phosphorylates MyoD on
Ser237 in vivo and in vitro. We demonstrated that a non-
phosphorylable Ala237 mutant of MyoD is never up-regu-
lated by Mos. These data show that direct Mos-dependent
phosphorylation of MyoD on Ser237 is involved in positively
regulating MyoD activity.
2. Materials and methods
2.1. Cell cultures, DNA transfection and luciferase assays
The 10T1/2 ¢broblastic cells were maintained in growth medium
supplemented with antibiotics (a mixture of penicillin and streptomy-
cin (Life Technologies)) and 15% of foetal calf serum (FCS) in Dul-
becco’s modi¢ed Eagle’s medium (DMEM). 10T1/2 cells were trans-
fected by using the polyethylenimine essentially as described [24].
Brie£y, 3U104 cells per well were plated onto 24-well plates. On the
following day, cells were transfected with various combinations of
plasmids as indicated in the ¢gure captions. The total amount of
DNA used for each plate was normalised with the respective empty
expression vector. Luciferase activity was determined in aliquots of
cell extracts from cells harvested 48 h after transfection in growth
medium with a luminometer (Lumat LB9507-DLA Bertholet) and
the Luciferase Assay System (Promega) as instructed by the manufac-
turer. One hundred ng of the pEGFP-C1 plasmid (Invitrogen) was
included in transfections as an internal control for transfection e⁄-
ciency. All luciferase activities were determined with equivalent quan-
tities of proteins in triplicate and repeated at least twice.
2.2. Plasmids
pEMSV-MyoD-wt was a generous gift from the H. Weintraub lab-
oratory. The pEMSV-MyoD-Ala200 mutant was obtained from M.
Kitzmann. The pEMSV-MyoD-Ala237 mutant and pET-MyoD-
Ala200 were generated by polymerase chain reaction with a 5P primer
(5P-GAGGCGGTGCGCGAGGCCAGGCCAGGGAAG-3P) and a
3P primer (3P-CTTCCCTGGCCTGGCCTCGCGCACCGCCTC-5P)
using pEMSV-MyoD-wt as template and the QuickChange1 site-di-
rected mutagenesis kit (Stratagene, Ozyme) as instructed by the man-
ufacturer. Expression vectors pCMV-HA-Moswt and pCMVHA-
MosKM were generated by cloning three hemaglutinin epitope tags
(3Tag HA) at the amino terminus of cDNA insert in pCDNA3 (In-
vitrogen). The reporter plasmid MCK-Luc (p1256-MCK), generously
provided by S. Hauschka [25], contains the promoter-enhancer region
from the mouse muscle creatine kinase. pET-MyoD-wt was obtained
from Vandromme et al. [26].
2.3. Puri¢ed proteins
The production and puri¢cation of MyoD-wt protein has been
described [22]. MyoD-Ala237 was puri¢ed by using the same protocol.
The active kinase Moswt and the inactive kinase MosKM proteins were
puri¢ed by immunoprecipitation from transfected cells. Whole cell
extracts were prepared in ice-cold RIPA-EGTA bu¡er (50 mM
HEPES, pH 7.6, 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 10
mM L-glycerophosphate, 0.1 mM Na2VO3, 1 mM NaF, 0.1% Tween
20, 10% glycerol, 1 mM DTT, 1 mM PMSF and 1 Wg/ml leupeptin,
1 Wg/ml aprotinin and 1 Wg/ml pepstatin). Lysates were centrifuged at
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4‡C for 10 min in a microfuge set at maximum speed and the super-
natant was stored at 380‡C in small aliquots. For immunoprecipita-
tion, precleared cell lysates in IP bu¡er (50 mM Tris, pH 7.4, 150 mM
NaCl, 10% glycerol, 0.5% NP40, 0.5 mM Na-orthovanadate, 50 mM
NaF, 80 mM L-glycerophosphate, 10 mM Na-pyrophosphate, 1 mM
DTT, 1 mM EGTA and 10 Wg/ml leupeptin, 10 Wg/ml pepstatin and
10 Wg/ml aprotinin) were incubated with the anti-HA antibodies for 2^
3 h at 4‡C with gentle agitation. Immunocomplexes bound to protein
G-Sepharose were collected by centrifugation and washed several
times in IP bu¡er.
2.4. In vitro kinase assays
Immunoprecipitated proteins were washed three times in washing
bu¡er (1% NP40, 0.15 M NaCl, 10 mM phosphate bu¡er (TPO4, pH
7), 1 mM EDTA and 1 mM sodium pyrophosphate). In vitro Mos
phosphorylation assays were done as described previously [19]. In
brief, protein kinase reaction mixtures (100 Wl ¢nal) included 1 mM
sodium pyrophosphate, 10 mM TPO4, pH 7.0, 150 mM NaCl, 10 mM
MnCl2, 2 mM DTT, 25 WM ATP, 50 WCi of (Q 32p) ATP (3000 Ci
mmol-1) and 0.5 to 2 Wg of puri¢ed MyoD-wt or MyoD-Ala237 pro-
teins. The reaction was incubated for 15 min at 30‡C and was termi-
nated by adding 50 Wl of 2U sodium dodecyl sulphate (SDS) sample
bu¡er. The mixture was boiled for 10 min and analysed by SDS^
polyacrylamide gel electrophoresis (PAGE).
2.5. Phosphopeptide mapping
Bacterially puri¢ed MyoD-wt protein (pET-MyoD-wt) was in vitro
phosphosphorylated by Moswt immunoprecipitated from transfected
cells as described above. The trypsin digest was analysed essentially as
previously described [13].
2.6. Antibodies and Western blot analyses
For immunoblot analysis, total cell extracts or immunoprecipitates
were solubilised in RIPA-EGTA bu¡er. Analyses were performed on
10% polyacrylamide gels with a 5% polyacrylamide stacking gel. Elec-
trophoretic transfer of proteins from SDS^PAGE gels to nitrocellu-
lose membranes were blocked with Tris^HCl 50 mM, pH 7.4, 150 mM
NaCl and 0.05% Tween 20 containing 5% skimmed milk and incu-
bated overnight at 4‡C with primary antibodies: polyclonal Emos1
anti-Mos antibody diluted 1/1000 prepared in rabbit [27], and poly-
clonal C20 anti-MyoD diluted 1/500 were provided by Santa Cruz
(Biotechnology, Santa Cruz, CA, USA). The monoclonal 12CA5
anti-HA antibody was provided by Boehringer (Mannheim, Ger-
many). Membranes were washed and incubated for 1 h with a
peroxidase-conjugated secondary antibody (Sigma) at a dilution of
1/10 000 with polyclonal antibodies and 1/4000 with monoclonal anti-
bodies. After several washes, membranes were incubated with an
enhanced chemiluminescence system (Amersham) according to the
manufacturer’s instructions. Exposure was done with Agfa Curix
RP2 ¢lms.
3. Results
3.1. Mos-dependent phosphorylation of MyoD
We previously reported that a GST^Mos fusion protein
activated by incubation in rabbit reticulocyte lysates was
able to phosphorylate bacterially produced MyoD in an in
vitro kinase reaction [18]. In the present work we used Mos
protein from cell extracts. Wild-type (wt) and kinase-inactive
Mos (KM) proteins were puri¢ed by immunoprecipitation
from transfected 10T1/2 cells (Fig. 1A). Kinase activity was
evidenced by autophosphorylation of the wild-type Moswt
(Fig. 1B, lanes 1 and 2) but not of the kinase-inactive
MosKM (Fig. 1B, lane 3). The immunoprecipitated Moswt
but not the kinase-inactive MosKM was able to phosphorylate
bacterially produced MyoD in an in vitro kinase reaction
(Fig. 1B, lane 2).
To map the site(s) phosphorylated on MyoD, we used tryp-
tic digestion of MyoD followed by 2D phosphotryptic peptide
mapping. As illustrated in Fig. 1C, one phosphotryptic pep-
tide was obtained after digestion of 32P-labeled MyoD. To
estimate which site is phosphorylated, we used the PhosPep-
sort program previously used in the determination of MyoD-
Ser200 as the major phosphorylation site of Cdk1 and Cdk2
[12,13]. According to the mobility prediction, the phospho-
Fig. 1. Mos kinase from transfected cells phosphorylates MyoD e⁄-
ciently. (A) 100 Wg of 10T1/2 cells transfected with an empty vector
(lane 1), HA-epitope-tagged Moswt (lane 2) and HA-MosKM (lane
3) were immunoprecipitated with the 12CA5 monoclonal antibody,
transferred onto nitrocellulose membrane and analysed by immuno-
blotting with the puri¢ed rabbit polyclonal anti-Emos 1 antibody.
(B) Duplicate samples of immunoprecipitates were used in an in vi-
tro kinase assay. Puri¢ed bacterially expressed MyoD [26] (1 Wg,
lanes 2 and 3) were added to immunoprecipitates and were incu-
bated in kinase bu¡er containing [Q-32P]ATP. Lane 1 shows auto-
phosphorylation of the Moswt protein. Proteins were separated by
SDS^PAGE and the phosphorylated proteins were visualised by
autoradiography. Exposure time was 4 h. (C) Phosphorylation sites
on MyoD were analysed by tryptic digestion followed by 2D pep-
tide mapping. The phosphopeptide map for in vitro phosphorylated
MyoD was performed on bacterially produced MyoD phosphorylat-
ed in vitro by Mos. The only phosphopeptide found is pointed to
by an arrow. Mobility prediction of MyoD tryptic phosphopeptide
by using the Mobility 4 program [11] shows the pattern of migra-
tion for the two phosphopeptides that could be phosphorylated by
Cdk1.
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peptide obtained after in vitro phosphorylation of MyoD by
Mos would correspond to phosphorylation of Ser237. This
result shows that Mos phosphorylates MyoD on one site
which is predicted to contain Ser237 and agrees with previous
data suggesting that Mos phosphorylates MyoD on serine
residue(s) located in the COOH terminal region [22].
3.2. Ser237 is the major site of Mos-dependent phosphorylation
of MyoD
To determine precisely the site for in vivo Mos-dependent
phosphorylation of MyoD, we mutated the serine 237 in
MyoD. The mutant was generated by site-directed mutagene-
sis replacing the amino acid serine by a non-phosphorylable
alanine residue and named MyoD-Ala237. Bacterially pro-
duced wild-type MyoD and its MyoD-Ala237 mutant were
subjected to phosphorylation by puri¢ed Mos kinase.
Phosphorylated proteins were separated by SDS^PAGE and
visualised by autoradiography. As expected, Mos kinase was
able to phosphorylate MyoD-wt but could not phosphorylate
MyoD-Ala237 (Fig. 2A). These data show that serine 237 is
necessary for MyoD phosphorylation in this in vitro kinase
assay. To extend to cell context, 10T1/2 cells were transfected
with an expression vector encoding either MyoD-wt or
MyoD-Ala237 in the absence or in the presence of Moswt.
Two days after transfection, cells were lysed and whole cell
extracts were subjected to 10% SDS^PAGE and MyoD was
detected by Western blot analysis. As shown in Fig. 2B,
MyoD-wt and MyoD-Ala237 migrated in SDS^PAGE as a
doublet containing equivalent amounts of fast and slowly mi-
grating forms (lanes 2 and 4) which probably represent di¡er-
ent phosphorylation isoforms of MyoD as previously ob-
served [28]. By contrast, when Moswt was co-transfected, a
hyperphosphorylated form of MyoD-wt but not of MyoD-
Ala237 accumulated as evidenced by using the polyclonal
anti-P-Ser antibody (Fig. 2B, lane 3 and 5).
However, few hyperphosphorylated forms of MyoD can be
detected when cells were transfected by the expression vector
encoding MyoD-Ala237. In proliferating myoblasts serine 200
Fig. 2. MyoD serine 237 is the major phosphorylation site of Mos.
(A) Puri¢ed bacterially produced MyoD-wt and/or MyoD-Ala237
proteins were incubated as in Fig. 1, in the presence of [Q-32P]ATP.
After the phosphorylation reaction, the di¡erent proteins were sepa-
rated by SDS^PAGE and visualised by autoradiography. The Coo-
massie blue stain of the protein substrates is also shown. (B) 10T1/2
cells were transfected with pEMSV-MyoD-wt (lanes 2 and 3) or
pEMSV-MyoD-Ala237 (lanes 4 and 5) alone or in combination
with pCMV-HA-Moswt (lanes 3 and 5). Forty-eight hours following
transfection, cells maintained in DMEM supplemented with 15%
FCS were harvested and Western blot analysis was performed. Ten
Wg of whole cell extracts were solubilised in SDS loading bu¡er.
After SDS^PAGE, HA-tagged Moswt proteins were detected by im-
munoblotting with the 12CA5 monoclonal antibody and MyoD pro-
teins were detected with the a⁄nity puri¢ed polyclonal C20 anti-
MyoD antibody. Cdk4 protein expression from the same whole ex-
tracts used as internal control was visualised with the anti-CdK4
(Santa Cruz). One hundred Wg of cell extracts were immunoprecipi-
tated with the monoclonal anti-MyoD antibody (Clone 5.8A, Phar-
mingen) and resuspended in SDS containing samples. The immuno-
precipitates were then subjected to SDS^PAGE and transferred to
nitrocellulose membrane. Phosphorylated MyoD was detected by
Western blot analysis using anti-phosphoserine antibody (Zymed).
(C) In growing medium phosphorylation of the serine 200 by cy-
clin^Cdk complexes masks the phosphorylation shift of MyoD-
Ala237 by the Mos kinase. 10T1/2 cells were transiently transfected
with MyoD-wt (lane 2), MyoD-Ala200 (lanes 3 and 4) in combina-
tion with HA-Moswt (lane 4) or the kinase-inactive HA-MosKM
(lanes 2 and 3). Twenty-¢ve Wg of whole cell extracts from 10T1/2
expressing proteins were directly solubilised in SDS loading bu¡er.
Proteins were separated by 10% SDS^PAGE. MyoD proteins were
analysed by Western blotting for MyoD and Mos expression. West-
ern blot showed that Moswt was able to phosphorylate the MyoD-
Ala200 protein as evidenced by its reduced gel mobility.
6
FEBS 23737 25-5-00
K. Pelpel et al./FEBS Letters 474 (2000) 233^237 235
is the major site of Cdk-dependent phosphorylation [12,13],
so, in order to distinguish Cdk-dependent phosphorylation
from Mos-dependent phosphorylation of MyoD, we used
the MyoD-Ala200 mutant. 10T1/2 cells were transfected
with MyoD-wt or MyoD-Ala200 with Moswt or the kinase-
inactive MosKM expression vectors and whole cell extracts
were subjected to Western blot analysis with the monoclonal
antibody 12CA5 directed against HA-tagged Mos or the anti-
MyoD antibody. When isolated from proliferating myoblasts
([28] and data not shown) or from cells cotransfected with
MyoD and the kinase-inactive MosKM (Fig. 2C, lane 2),
MyoD migrated in SDS^PAGE as a doublet containing fast
and slow migrating forms while MyoD-Ala200 showed only a
fast migrating form that was shown to be the hypophosphory-
lated species of MyoD [12,13]. However, we have previously
shown that these two bands were resolved in a single fast
migrating band after phosphatase treatment [28]. This result
shows that MyoD is present under di¡erent phosphorylation
states in myoblasts. In contrast, MyoD-Ala200 isolated from
cells transfected with Moswt contained high levels of the slow
migrating species (Fig. 2C, lane 4). In agreement with pre-
vious data, MyoD-Ala200 was expressed at higher levels
than MyoD-wt, due to the stabilisation of the protein [13].
Altogether these data indicate that MyoD could be phosphor-
ylated on Ser237 and that MyoD phosphorylation in the pres-
ence of Moswt was not due to Cdk-dependent phosphory-
lation.
3.3. Replacement of Ser237 to Ala237 in MyoD suppresses
enhanced muscle gene-speci¢c transacting activity by Mos
In an attempt to assess the consequence of Ser237 phos-
phorylation on MyoD activity, we tested abilities of MyoD-wt
and MyoD-Ala237 to transactivate muscle-speci¢c gene ex-
pression in the absence or presence of active Mos kinase
(Moswt). Plasmids expressing either MyoD-wt or MyoD-
Ala237 alone or together with Moswt were transfected in
10T1/2 cells with a reporter plasmid containing the muscle
creatine kinase promoter-enhancer driving the luciferase
gene (MCK-Luc). Transfected cells were grown in proliferat-
ing medium for 48 h and transactivation of the reporter gene
estimated by luciferase assays. No signi¢cant luciferase activ-
ity was observed when MCK-Luc was cotransfected with the
empty expression plasmid (pEMSV) or the expression vector
encoding the Mos kinase (Moswt) (Fig. 3, lanes 1 and 2). In
addition, we have previously shown that Mos expression has
no e¡ect on the pEMSV promoter which drives MyoD ex-
pression [22]. As expected, luciferase activity was highly en-
hanced by MyoD-wt and MyoD-Ala237. Moreover, in the
presence of Mos the level of MCK-luciferase activity was
three-fold higher than that obtained with MyoD-wt alone.
In contrast such an increase was not observed with the
MyoD mutant Ala237 (Fig. 3, lanes 3 to 6). As previously
shown, this accumulation of MyoD was not due to its meta-
bolic stabilisation by Mos expression but to the activation of
the positive autoregulation loop of MyoD [23]. Altogether our
results clearly indicate that the increase in MyoD activity in
response to Mos is due to a direct phosphorylation on MyoD
protein and is not associated with hypothetical e¡ects exerted
by Mos on the obligate E partners: in vitro as well as in vivo
we have never found a physical interaction between Mos and
E-proteins nor a phosphorylation of the E-proteins by the
Mos kinase [22,23]. In contrast, it has been recently shown
that casein kinase II (CKII) increases the transcriptional ac-
tivities of MyoD and MRF4, but independently of their direct
phosphorylation [17].
Interestingly, sequence alignment revealed that serine at
position 237 in MyoD is nearly identical in the transcription
activation domains of myogenin (Ser204) and MRF4 (Ser189)
but is missing in Myf-5, E12 and E47 proteins. This conser-
vation suggests that this serine residue could be the Mos (or a
related kinase) phosphorylation sites that play an important
role in regulating the function of myogenic factors during the
course of di¡erentiation. In this context, it is noteworthy that,
on the one hand, the phosphorylation of mos gene products
(v-Mos/c-Mos) plays a key role in regulating its function (re-
view in [29]) and, on the other hand, that PKA overexpression
inhibits myogenesis by targeting molecules other than the
MRFs [9]. Then, in vitro phosphorylation of v-Mos/c-Mos
by PKA indicated that PKA inhibits v-Mos via phosphory-
lation on its Ser263, equivalent to residue ser232 in mouse c-
Mos [30]). Thus, a set of phosphorylations implying c-Mos,
PKA and MRF proteins could constitute one of the regula-
tory pathways of myogenic di¡erentiation.
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